#CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results
CV Sciences, Inc. has announced its financial results for the fiscal year ending December 31, 2025, revealing a decline in revenue yet significant improvements in gross margins and adjusted EBITDA. The consumer wellness company continues to navigate a challenging regulatory environment while focusing on its strategic growth initiatives.
#Financial Overview
The company's total revenue for fiscal 2025 reached $13.8 million, dropping from $15.7 million in the previous year. This decrease is attributed primarily to temporary out-of-stock situations affecting key products and existing regulatory constraints that have impacted sales volumes. Despite the decline in revenue, CV Sciences achieved a notable improvement in gross margin, rising to 49.0% from 45.6% in 2024.
#Quarterly Performance
In the fourth quarter of 2025, CV Sciences reported revenues of $3.3 million, consistent with the third quarter but down from $3.9 million in the same quarter of 2024. The gross margin for this quarter was recorded at 50.5%, a significant increase from 43.2% in the fourth quarter of 2024. This improvement reflects ongoing efforts to optimize operations and reduce costs.
#Adjusted EBITDA and Operating Loss
The company recognized an adjusted EBITDA loss of $0.3 million for the fiscal year, markedly better than a loss of $0.8 million in 2024. Additionally, positive adjusted EBITDA of $0.1 million was achieved in the fourth quarter, signaling enhanced operational performance compared to losses reported in the previous quarters.
#Cost Management and Product Launches
CV Sciences has successfully reduced its operating expenses by 17.2% to $7.7 million for 2025, down from $9.4 million in 2024. This reduction helped the company lower its operating loss to $0.5 million from $2.2 million the prior year. Furthermore, they have expanded their product line with recent launches, including Ignite and EMPOWR, designed to meet growing consumer demands.
#Future Outlook
As CV Sciences moves into 2026, the company plans to build on its recent momentum with a focus on operational efficiencies and sustained positive cash flow. The leadership expressed a commitment to bolstering growth through targeted acquisitions that align with their existing product offerings, aiming for an overall improvement in long-term shareholder value.
#Key Takeaways
- CV Sciences reported a revenue decline to $13.8 million for fiscal 2025, down from $15.7 million in 2024.
- Gross margin increased to 49.0%, reflecting enhanced operational efficiency.
- Adjusted EBITDA loss improved to $0.3 million for the fiscal year, with a positive adjusted EBITDA of $0.1 million in Q4 2025.
- Operating expenses decreased by 17.2%, contributing to reduced losses.
- Recent product launches aim to enhance market opportunity and align with consumer trends.
Original source: Read original article